Manipulation of Dendritic Cells for Tumor Immunity

ISSN: 1875-614X (Online)
ISSN: 1871-5230 (Print)

Volume 15, 3 Issues, 2016

Download PDF Flyer

Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry

Formerly: Current Medicinal Chemistry - Anti-Inflammatory and Anti-Allergy Agents

Aims & ScopeAbstracted/Indexed in

Submit Abstracts Online Submit Manuscripts Online

Claudiu T. Supuran
Neurofarba Department
University of Florence

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Manipulation of Dendritic Cells for Tumor Immunity

Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry, 6(2): 151-160.

Author(s): Hideho Okada and Lisa H Butterfield.

Affiliation: University of Pittsburgh Cancer Institute G12.a Research Pavilion at the Hillman Cancer Center 5117 Centre Ave. Pittsburgh, PA, 15213-1863, USA.


Although animal studies have shown that tumor antigen (TA)-pulsed dendritic cell (DC)-based vaccines can mediate antitumor effects in vivo, human clinical trials utilizing this strategy have thus far had only modest success. In an effort to improve the efficacy of tumor vaccines, numerous investigators have explored the genetic engineering of DC to impart cytokine or TA-expression capability on DC. These efforts have focused on enhancing TA presentation and as well as subsequent T-cell activation and expansion. This chapter reviews recent progress in studies aimed to potentiate the efficacy of DC-based vaccines by genetic engineering of DCs with cDNAs encoding immuno-stimulatory cytokine-genes or TAs.


DC-based vaccines, tumor antigens, gene-silencing, GM-CSF, Immunological Microenvironment.

Purchase Online Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 6
Issue Number: 2
First Page: 151
Last Page: 160
Page Count: 10
DOI: 10.2174/187152307780598054
Price: $58

Related Journals

Webmaster Contact: Copyright © 2016 Bentham Science